• Enabling the possibility for a universal
    bone marrow transplant solution for patients
    with cancers and rare genetic diseases

  • Pioneering

  • Novel cellular and
    immune therapeutics

Latest Updates

Dec 2017
Dec 11, 2017

Gamida Cell Investor Event at ASH

See the Webcast >
Jan 2018
Jan 16, 2018

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

Read More >
Dec 2017
Dec 11, 2017

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

Read More >
Nov 2017
Nov 20, 2017

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

Read More >

Gamida Cell is committed to changing the treatment paradigm for patients with cancer and rare genetic diseases.

One Technology:
Many Applications

Gamida Cell’s world-class scientists have developed a technology that offers the potential of curative cellular and immune therapeutics for a diverse population of patients in need. The proprietary NAM technology, which harnesses epigenetics to increase the population of functional cells in culture, is utilized to develop a broad pipeline of best-in-class therapies to treat cancer and rare genetic diseases.

Innovative Treatments

  • NiCord®


    A Curative Treatment for High-Risk Blood Cancers

  • CordIn™


    A Curative Treatment for Rare Genetic Diseases

  • NAM-NK Cells

    NAM-NK Cells

    An immunotherapy for Blood Cancers and Solid Tumors